Comparative Pharmacology
Head-to-head clinical analysis: FOSFOMYCIN TROMETHAMINE versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSFOMYCIN TROMETHAMINE versus XIFYRM.
FOSFOMYCIN TROMETHAMINE vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which catalyzes the first step of peptidoglycan biosynthesis.
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
3 g orally once as a single dose for uncomplicated urinary tract infection.
500 mg orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life is 5.7 hours (range 3-8 hours) in patients with normal renal function; approximately 50 hours in end-stage renal disease (CrCl <10 mL/min).
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
Primarily excreted unchanged in urine via glomerular filtration (approximately 90% of absorbed dose within 24-48 hours); small amount (approximately 10%) excreted in feces via biliary elimination.
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category A/B
Category C
Antibiotic
Antibiotic